Intas Pharmaceuticals Entered into a Collaboration and License Agreement with mAbxience for Etanercept Biosimilar to Treat Autoimmune Diseases
Shots:
- Intas Pharmaceuticals signed a strategic exclusive licensing agreement with mAbxience for Etanercept biosimilar for the treatment of autoimmune diseases
- Under the terms of the agreement, Intas receives the exclusive rights to commercialize Etanercept biosimilar across more than 150 countries worldwide, incl. Europe & the US, for the treatment of various autoimmune diseases. Moreover, mAbxience will be responsible for the development, manufacturing & distribution of the Etanercept biosimilar
- The financial terms of the transaction under the collaboration were undisclosed.
Ref: PR Newswire | Image: Intas
Related News:- Intas and Dong-A ST Report EMA Acceptance of MAA for DMB-3115, a Proposed Biosimilar to Stelara (ustekinumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
